



Sir Charles Gairdner Hospital Guideline#

**Title: ABDOMINAL PARACENTESIS IN CHRONIC LIVER DISEASE**

**This Revision Issued:** 1<sup>st</sup> November 2013

**GUIDELINE STATEMENT:**

SCGH Operates in accordance with  
Hospital Policy #013 Informed Consent  
This guideline provides hospital specific guidance to  
Medical staff, Nursing staff

**Scope:** Medical and Nursing management of paracentesis

**Responsibilities:**

**Medical:**

Written informed consent as Hospital Policy #013  
Performing diagnostic paracentesis and / or insertion of drain for therapeutic paracentesis  
Ensure venous access available, coagulation profile available from previous 24hrs  
Prescribe 20% Normal Serum Albumin (NSA) prior to commencement of therapeutic paracentesis

**Nursing:**

Monitoring of patient during paracentesis  
Monitoring of drainage, removal of drain and post procedure care

**Introduction**

- The development of refractory ascites in the setting of cirrhosis is associated with a 50% 2-year survival.
- All cases should be discussed with the Hepatology team.
- Spontaneous bacterial peritonitis (SBP) may be asymptomatic and can only be excluded by ascitic fluid analysis
- Dietary sodium restriction and diuretic therapy (not therapeutic paracentesis) are the first line treatment for ascites.
- Paracentesis may be diagnostic (typically 20mls fluid removed for analysis) or therapeutic (large volume paracentesis, drain to dry)
- Abdominal paracentesis is generally well tolerated and is frequently done as an outpatient.
- Risk of bleeding is low; need for correction of coagulopathy should be individualised
- Consider individualised requirement for intravenous antibiotics. All Childs C patients to receive one dose of intravenous Tazocin prior to therapeutic paracentesis.

**Diagnostic Paracentesis Indications**

- New onset ascites or ascites of unknown origin
- Patient with known ascites with fever, abdominal pain, hypotension, encephalopathy, or general deterioration.

**Therapeutic Paracentesis Indications**

- Large/Tense ascites or diuretic failure/resistance. The rationale behind this procedure is to improve patient comfort.
- Large ascites in the presence of a symptomatic hepatic hydrothorax

**Contraindications to diagnostic/therapeutic paracentesis**

- Uncooperative patient
- Acute abdomen that requires surgery
- Intra-abdominal adhesions
- Distended bowel
- Pregnancy
- Disseminated intravascular coagulation
- Inexperienced doctor

**Additional Contraindications to therapeutic paracentesis**

- If patient does not have symptoms do not perform
- Spontaneous Bacterial Peritonitis
- Hypotension
- Do not perform if patient has hepatorenal syndrome or acute renal failure, renal function will deteriorate. 3L can be removed for comfort.
- Relative indications include: frail patient, systemic or local infection

**List of equipment**

**Diagnostic Paracentesis**

Catheter pack  
Sterile fenestrated drape or towel  
Sterile gown  
PPE: sterile gloves / goggles  
19G x 1 ½" (white) drawing up needle  
20ml syringe (for fluid aspiration)  
Chlorhexidine 2% in 70% alcohol  
Absorbent sheet  
Adhesive absorbent dressing (e.g. Post op Opsite™)  
Blood culture bottles  
Sterile yellow top container, Clotted tubes

**Therapeutic Paracentesis add**

Lignocaine 1% 50mg in 5ml  
23G x 1" (orange) needle  
10ml syringe (for local anaesthesia)  
Pharmaceal™ – Thoracentesis/  
Abdocentesis kit (includes drainage tube and scalpel)  
2 x occlusive dressing (e.g. Tegaderm™ or stat lock small (6-8.5fr)™)  
Drainage bag (2 litre luer lock) and holder  
Wet strength bag  
NSA 20% 100ml

**Safety Information**

**Diagnostic or Therapeutic Paracentesis**

- Patient must be identified by three indicators (e.g. name, DOB, address or URM)
- Explain the procedure to the patient including complications (infection, punctured viscera, bleed, and hypovolaemia). Written consent as per Hospital Policy 013
- Record baseline core observations
- Prophylactic infusions of plasma or platelets not required for diagnostic paracentesis
- Ask the patient to empty their bladder pre procedure
- Position patient on his / her back in a slightly recumbent position leaning toward the site of paracentesis
- Examine abdomen for optimal site. Ideally the right or left Iliac fossa, 2 finger breadths cephalad and 2 finger breadths medial to the ASIS
- Check the area is dull to percussion and confirm shifting dullness. If there is clinical doubt regarding the presence of ascites, then the paracentesis should be guided using ultrasound.

- Exclude significant hepatomegaly, splenomegaly, visible vessels or scars in the area. Avoid the inferior epigastric artery which runs along the edge of the rectus sheath.

### **Diagnostic Paracentesis:**

#### **Procedure**

Maintain standard aseptic technique at all times. Follow the risk assessment outlined in the Aseptic Technique Framework available at SCGH Intranet/Department/Infection Control Manual/ Aseptic Technique Policy No.18”

- Clean trolley/work surface with pre-diluted detergent and water or detergent wipe.
- Gather equipment for the procedure.
- Perform hand hygiene and prepare sterile field using a non touch technique
- Don sterile gloves and gown
- Place sterile fenestrated drape or towel at proposed site
- Clean the area with Chlorhexidine 2% in 70% alcohol for a minimum of 30 seconds, allow to dry for 20-30 seconds
- Using the 19g needle and 20ml syringe advance the needle while aspirating. Once a flashback is seen do not advance further but continue to aspirate approx. 20mls of ascites
- If you cannot get fluid, reposition the needle without removing from skin. If still there is no fluid, pull out needle, use new sterile needle and syringe and repeat.
- If you are unable to aspirate fluid request ultrasound guided
- If a therapeutic paracentesis is not required cover the aspiration site with a post op Opsite™ dressing using a non touch technique.
- Dispose of waste appropriately.
- Remove gloves and gown and perform hand hygiene.
- Clean trolley after use with pre-diluted detergent and water or detergent wipe

### **Therapeutic Paracentesis**

#### **Procedure**

- Perform a diagnostic paracentesis procedure as described above to confirm the ideal location for the drain.
- Maintain aseptic non touch technique
- Inject local anaesthetic
- Make small incision (<3mm) with a scalpel
- Insert the drain using Z technique (pull the adjacent skin down and toward the midline during insertion then release). If you are unable to aspirate fluid request ultrasound guided.
- Secure drain to skin with dressings ensuring drain is not kinked (suture should not be used).
- Attach the drainage bag to the drain.
- Alert the nurse that the drain has been inserted.

#### **Procedure notes**

- Write a procedure note documenting: site, time, and consent, indications for procedure, character of fluid, any complications and analysis of ascites requested.

## **Nursing Management of paracentesis drain**

### **Safety Information**

- Patient to remain in bed while drain in situ and until NSA infusion complete (see below)
- Patients can experience hypotension or decreased urine output related to paracentesis induced circulatory dysfunction for up to five days post therapeutic paracentesis

### **Pre Procedure**

- Record patient's weight prior to drain insertion.
- Ensure patient has recently emptied their bladder to minimise risk of perforation
- Observe and support patient throughout insertion procedure

### **Drainage of Ascites**

- Record core observations ½ hrly for 1hr then hourly until drainage complete / discharge from short stay areas
- Drainage should be continuous, do not clamp tubing or interrupt drainage unless specifically instructed by senior Hepatologist
- Drains inserted in the radiology department: radiology department to attach a 2 litre drainage bag to catheter, leave unclamped allowing free drainage on return escort to ward
- Record ascitic drainage on fluid balance chart (MR 904) or clinical pathway (MR710)
- Replace ascites at start of procedure or on return from radiology department
  - One bottle, 100mls 20% NSA
  - Then one bottle 100mls 20% NSA for every 3litres drained, (unless otherwise specified)
  - Each bottle of NSA infused over one hour
- Observe puncture site for any leakage around drain and report
- If fluid stops draining prematurely, contact medical officer

### **Drain removal**

- Remove drain after a maximum of 6 hours or before if drainage stops
- Remove drain (as per NPG 65)
- Apply sterile dry dressing and adhesive occlusive secondary dressing.

### **Post drain removal**

- Record patient's weight.
- Assist patient when first mobilised post procedure, risk of postural hypotension and falls
- If fluid leakage occurs, lay patient on opposite side to insertion site for 2 hrs.
- If excessive drainage, apply wound management bag over site
- Consider suture if fluid leakage continues for > 24hrs.
- Continue to document any further drainage of ascitic fluid on FBC (MR 904) or clinical pathway MR710
- Consider further NSA 20% replacement if drainage continues, in consultation with medical team

- Observe for signs of secondary peritonitis, haematuria, post paracentesis circulatory dysfunction (hypotension, reduced urine output) can occur up to 6 days post procedure
- Discharge education: Inform patient of potential signs and symptoms

### **Ascitic fluid analysis (Routine)**

- Microscopy and WCC + differential (yellow top sterile container to Microbiology)
- Blood culture bottles
- Albumin concentration and serum albumin concentration (clotted blood tube to Biochem)

#### **Interpretation**

- If the polymorphonuclear leucocyte count is  $>250$  cells/mm<sup>3</sup> => SBP
- Discuss all cases of SBP with Hepatology.
- Serum-ascites albumin gradient = serum albumin - ascitic fluid albumin if  $>1.1$  g/dL portal hypertension is present; if  $< 1.1$  g/dL portal hypertension is not present (about 97% accurate)

### **Ascitic fluid analysis (Specific additional investigations)**

- Microbiology for AFB, PCR and culture for mycobacteria – only if there is high index of catuberculosis
- Cytology – suspicion of peritoneal carcinomatosis
- Lactate dehydrogenase  $>225$ mU/L, glucose  $<50$ mg/dL, total protein  $>1$ g/dL and multiple organisms on culture suggest secondary bacterial peritonitis (ruptured viscus or loculated abscess)
- A high level of triglycerides confirms chylous ascites.
- An elevated amylase level suggests pancreatitis or gut perforation.
- An elevated bilirubin level suggest biliary or gut perforation

## **Bibliography:**

- Bendtsen, F, Gronbaek, H, Hansen, J, Aagaard, N, Schmidt, L & Moller, S 2012, 'Treatment of ascites and spontaneous bacterial peritonitis - part 1', *Danish Medical Journal*, vol. 59, no. 1, C4371. (Guideline)
- Bernardi, M, Caraceni, P, Navickis, RJ & Wilkes, MM 2012, 'Albumin infusion in patients undergoing large-volume paracentesis: A meta-analysis of randomized trials', *Hepatology*, vol. 55, no. 4, pp. 1172-81. (Level I)
- Caraceni, P, Domenicali, M, Tovoli, A, Napoli, L, Ricci, CS, Tufoni, M & Bernardi, M 2013, 'Clinical indications for the albumin use: Still a controversial issue', *European Journal of Internal Medicine*, viewed 2 September 2013, <http://dx.doi.org/10.1016/j.ejim.2013.05.015>. (Expert opinion)
- Carey, A-m & Barnett, L 2013, 'Paracentesis for Malignant Ascites Procedure', *Doncaster and Bassetlow Hospitals, NHS Foundation, PAT/T56 v. 1*, Viewed 4 September 2013, from [http://www.dbh.nhs.uk/freedom\\_of\\_information/information\\_classes/Patient\\_Policies/Treatments\\_and\\_Investigations.aspx](http://www.dbh.nhs.uk/freedom_of_information/information_classes/Patient_Policies/Treatments_and_Investigations.aspx). (Guideline)
- Gines, P, Angeli, P, Lenz, K, Møller, S, Moore, K, Moreau, R, Merkel, C, Larsen, HR, Bernardi, M, Garcia-Tsao, G & Hayes, P 2010, 'EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis', *Hepatology*, vol. 53, pp. 397-417. (Guideline)
- McGibbon, A, Chen, G, Peltekian, K & Veldhuyzen Van Zanten, S 2007, 'An evidence-based manual for abdominal paracentesis', *Digestive Diseases and Sciences*, vol. 52, no. 12, pp. 3307-15. (Level IV)
- Moore, K & Aithal, G 2006, 'Guidelines on the management of ascites in cirrhosis', *Gut*, vol. 55, Supp IV, pp. vi1-vi12. (Guideline)
- Pache, I & Bilodeau, M 2005, 'Severe haemorrhage following abdominal paracentesis for ascites in patients with liver disease', *Alimentary Pharmacology & Therapeutics*, vol. 21, pp. 525-529. (Level IV)
- Runyon, B 2013, *Management of adult patients with ascites due to cirrhosis: Update 2012* [Online]. American Association for Study of Liver Disease. Viewed 28 August 2013 from <http://www.aasld.org/practiceguidelines/Documents/ascitesupdate2013.pdf>. (Guideline)
- Sachs, B 2013, 'Abdominal Paracentesis: Clinician Information'. *Evidence Summaries*, viewed 01 August 2013, JBI COnNECT, JBI Database of Evidence Based Best Practices, ID: JBI543. (Guideline)
- The Joanna Briggs Institute 2011 'Abdominal Paracentesis', *Evidence Summaries*, viewed 01 August 2013, JBI COnNECT, JBI Database of Evidence Based Best Practices, ID: JBI836. (Guideline)
- Thomsen, T, Shaffer, R, White, B & Setnik, G 2006. 'Paracentesis', *The New England Journal of Medicine*, vol. 355, no. 19, p. e21. (Expert opinion)

Wong, F 2012, 'Management of ascites in cirrhosis'. *Journal of Gastroenterology and Hepatology*, vol. 27, no. 1, pp. 11-20. (Expert opinion)

<b>RISK STATEMENT:</b>		
Non-compliance with this guideline will (please tick all that apply [right click on box, change properties, checked]):		
<i>Breach legislative requirements</i>	<input type="checkbox"/>	<i>Impact on Patient Quality of Care</i> <input checked="" type="checkbox"/>
<i>Breach National/State/Hospital Policy</i>	<input type="checkbox"/>	<i>Impact on Patient Safety</i> <input checked="" type="checkbox"/>
<i>Breach professional standards</i>	<input checked="" type="checkbox"/>	<i>Other:</i>
<i>Breach SCGH Mission &amp; Values</i>	<input checked="" type="checkbox"/>	

<b>Endorsing Authority:</b>	
Endorsed by:	Medical Executive Committee (MEC) Prof G Jeffrey Head of Department Hepatology
Policy Author:	Dr R Mac Nicholas Hepatologist SRN Sarah Byrne G63 Clinical Nurse Specialist Dr S Slatyer CNR
Executive Sponsor:	Dr V Cheng (MSD Medical Codirector)
1 <sup>st</sup> Issued on:	Nov 2013
Next review due:	<b>Nov 2016</b>
Version:	<b>1</b>
<b>References (Standards):</b>	
National Standard/s	Standard 2 partnering with consumers. Standard 3 preventing and Controlling Healthcare Associated Infection. Standard 9 Recognising and Responding to Clinical Deterioration in Acute Healthcare
Legislation	N/A
Standards	N/A
Related Documents	N/A